[Click eStock] "Samchundang Pharmaceutical, New Business Performance Expected with Platform Technology Acquisition"

[Asia Economy Reporter Hyunseok Yoo] Cape Investment & Securities analyzed on the 2nd that Samchundang Pharmaceutical is expected to achieve new business results through securing platform technology. The investment opinion of 'Buy' and the target stock price of 80,000 won were maintained.

Samchundang Pharmaceutical announced the S-Pass technology, which can convert injectable drugs into oral formulations, at a corporate presentation on the 1st. It explained its technological superiority compared to competitors based on preclinical trial results for each project, including Insulin, GLP-1, and Etanercept (biopharmaceutical product name: Enbrel).

The main points include faster action and prolonged drug release compared to IV/SC (intravenous/subcutaneous injection), 10 to 100 times more effective than competing technologies due to high absorption rate and low cost, rapid approval possible using FDA-approved polymers, minimized side effects by not using oil or antacids, and high safety for chronic patients requiring long-term medication by not using surfactants.

Researcher Hyungsu Kim of Cape Investment & Securities said, "Converting injectable drugs into oral formulations that enhance patient convenience and compliance is the direction pursued by all domestic pharmaceutical companies," adding, "The S-Pass technology is a platform technology that enables oral conversion even for large molecular biopharmaceuticals, allowing various injectable products to be converted into oral forms."

He emphasized, "Based on the preclinical trial results secured by the S-Pass technology, new business outcomes are achievable," and "Securing platform technology makes it possible to expect new business results."

This content was produced with the assistance of AI translation services.